AUTOIMMUNE INC. REPORTS THIRD QUARTER AND NINE
MONTHS 1993 FINANCIAL RESULTS

Lexington, Massachusetts, October 29, 1993 -- AutoImmune Inc. (Nasdaq: AIMM) today reported a net loss of $1,840,000, or $.18 per share, for the quarter ended September 30, 1993, compared with a net loss of $818,000 or $.55 per share, for the same quarter a year earlier. This brings the net loss for the year to date 1993 to $4,838,000 or $.52 per share, and compares to a net loss of $2,211,000 or $1.49 per share for the comparable period in 1992. Research and development expenses increased to $4,894,000 for the nine months 1993 from $2,651,000 in the comparable 1992 period, reflecting the costs of clinical studies for the Company's product portfolio.

"We continue to move along the course we have charted for 1993," said Robert C. Bishop, Ph.D., President and Chief Executive Officer for AutoImmune. "During the third quarter, the encouraging results of our Phase II clinical trial of AI-200 in rheumatoid arthritis were published in the September 24, 1993 issue of Science, and we are now preparing to conduct a dosing study. We have half of the patients enrolled in our Phase II study of AI-300 for uveitis, and we expect to begin a Phase I safety study of AI-401 in diabetes before year end. Preparations continue for our Phase II/III trial of AI-100 in multiple sclerosis, which is expected to start during the first quarter of 1994," Dr. Bishop stated.

"We are also very pleased that we have been able to recruit outstanding professionals, with 33 employees on board as of September 30th. Expansion of the laboratory facilities at our current location is now in the planning stages," Dr. Bishop added.

AutoImmune Inc. is developing pharmaceutical products based on the principle of oral tolerance for the treatment of immune system disorders, including multiple sclerosis, rheumatoid arthritis and uveitis.